Risk-Adapted Therapy for Clinical Stage I–II Hodgkin’s Disease: 7-Year Results of Radiotherapy Alone for Low-Risk Disease, and ABVD and Radiotherapy for High-Risk Disease

2000 ◽  
Vol 12 (5) ◽  
pp. 278-288 ◽  
Author(s):  
R. G. MacKenzie ◽  
E. Franssen ◽  
R. Wong ◽  
C. Sawka ◽  
N. Berinstein ◽  
...  
Keyword(s):  
High Risk ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Clinical Stage ◽  
Low Risk ◽  
Stage I ◽  
High Risk Disease ◽  
Radiotherapy Alone

Radiotherapy Alone in the Treatment of Clinical Stage I-IIA, Nonbulky, Hodgkin’s Disease

2002 ◽  
Vol 25 (2) ◽  
pp. 149-152 ◽  
Author(s):  
Renzo Mazzarotto ◽  
Caterina Boso ◽  
Giovanni Scarzello ◽  
Domenico Rubello ◽  
Dario Casara ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Clinical Stage ◽  
Stage I ◽  
Radiotherapy Alone

Results of a Prospective Trial of Mantle Irradiation Alone for Selected Patients With Early-Stage Hodgkin’s Disease

2001 ◽  
Vol 19 (3) ◽  
pp. 736-741 ◽  
Author(s):  
Kendall H. Backstrand ◽  
Andrea K. Ng ◽  
Ronald W. Takvorian ◽  
Ellen L. Jones ◽  
David C. Fisher ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Early Stage ◽  
Hodgkin’S Disease ◽  
Clinical Stage ◽  
Prospective Trial ◽  
Stage I ◽  
Mixed Cellularity ◽  
European Organization ◽  
Extended Field

PURPOSE: To determine the efficacy of mantle radiation therapy alone in selected patients with early-stage Hodgkin’s disease. PATIENTS AND METHODS: Between October 1988 and June 2000, 87 selected patients with pathologic stage (PS) IA to IIA or clinical stage (CS) IA Hodgkin’s disease were entered onto a single-arm prospective trial of treatment with mantle irradiation alone. Eighty-three of 87 patients had ≥ 1 year of follow-up after completion of mantle irradiation and were included for analysis in this study. Thirty-seven patients had PS IA, 40 had PS IIA, and six had CS IA disease. Histologic distribution was as follows: nodular sclerosis (n = 64), lymphocyte predominant (n = 15), mixed cellularity (n = 3), and unclassified (n = 1). Median follow-up time was 61 months. RESULTS: The 5-year actuarial rates of freedom from treatment failure (FFTF) and overall survival were 86% and 100%, respectively. Eleven of 83 patients relapsed at a median time of 27 months. Nine of the 11 relapses contained at least a component below the diaphragm. All 11 patients who developed recurrent disease were alive without evidence of Hodgkin’s disease at the time of last follow-up. The 5-year FFTF in the 43 stage I patients was 92% compared with 78% in the 40 stage II patients (P = .04). Significant differences in FFTF were not seen by histology (P = .26) or by European Organization for Research and Treatment of Cancer H-5F eligibility (P = .25). CONCLUSION: Mantle irradiation alone in selected patients with early-stage Hodgkin’s disease is associated with disease control rates comparable to those seen with extended field irradiation. The FFTF is especially favorable among stage I patients.

Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone

1992 ◽  
Vol 22 (5) ◽  
pp. 859-865 ◽  
Author(s):  
M.K. Gospodarowicz ◽  
S.B. Sutcliffe ◽  
R.M. Clark ◽  
A.J. Dembo ◽  
P.J. Fitzpatrick ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Clinical Stage ◽  
Stage I
Sign in / Sign up

Export Citation Format

Share Document